Effect of pioglitazone on reducing proteinuria in children and adolescents with nephrotic syndrome

The effect of pioglitazone on reducing proteinuria in pediatric patients with complicated nephrotic syndrome: Single-arm before–after clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20260511069359N1

Enrollment

Registered

2026-05-16

Start date

2026-06-05

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complicated Nephrotic Syndrome in Children and Adolescents. Nephrotic syndrome

Interventions

Intervention group: Eligible patients will receive oral pioglitazone in addition to the standard treatment for nephrotic syndrome. Pioglitazone will be administered at a dose of 0.5 milligrams per kil

Eligibility

Sex/Gender

All

Age

2 Years to 18 Years

Inclusion criteria

Inclusion criteria: Age between 2 and 18 years Diagnosis of frequently relapsing Or diagnosis of steroid-resistant nephrotic syndrome Receiving prednisolone at a minimum dose of 0.5 mg/kg/day Estimated glomerular filtration rate (eGFR) > 60 ml/min/1.73 m² Written informed consent obtained from parents or legal guardians

Exclusion criteria

Exclusion criteria: Diabetes or abnormal blood glucose eGFR = 60 mL/min/1.73 m² Underlying cardiac disease Heart failure Secondary nephrotic syndrome

Design outcomes

Primary

Measure	Time frame
Reduction in urine protein-to-creatinine ratio (UPCR) after pioglitazone administration compared with baseline in pediatric patients with complicated nephrotic syndrome. Timepoint: Measurement of urine protein-to-creatinine ratio (UPCR) at baseline (before initiation of pioglitazone treatment) and 3 months after the intervention. Method of measurement: Measurement of urine protein-to-creatinine ratio using urine sample analysis and standard biochemical laboratory methods.	—

Measure

Time frame

Reduction in urine protein-to-creatinine ratio (UPCR) after pioglitazone administration compared with baseline in pediatric patients with complicated nephrotic syndrome. Timepoint: Measurement of urine protein-to-creatinine ratio (UPCR) at baseline (before initiation of pioglitazone treatment) and 3 months after the intervention. Method of measurement: Measurement of urine protein-to-creatinine ratio using urine sample analysis and standard biochemical laboratory methods.

—

Secondary

Measure	Time frame
Change in serum albumin level after administration of pioglitazone compared with baseline in pediatric patients with complicated nephrotic syndrome. Timepoint: Measurement of serum albumin level at baseline (before initiation of pioglitazone treatment) and three months after the intervention. Method of measurement: Measurement of serum albumin level using blood sample analysis and standard biochemical laboratory methods.	—

Measure

Time frame

Change in serum albumin level after administration of pioglitazone compared with baseline in pediatric patients with complicated nephrotic syndrome. Timepoint: Measurement of serum albumin level at baseline (before initiation of pioglitazone treatment) and three months after the intervention. Method of measurement: Measurement of serum albumin level using blood sample analysis and standard biochemical laboratory methods.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactArash Abasi

Tehran University of Medical Sciences

arash.ped@gmail.com+98 21 6147 9999

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Jun 11, 2026